Treatment of rheumatoid arthritis by TNF-blocking agents

被引：18

作者：

Graninger, W ^{[1
]}

Smolen, J ^{[1
]}

机构：

[1] Univ Vienna, Gen Hosp, Div Rheumatol, A-1090 Vienna, Austria

来源：

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY | 2002年 / 127卷 / 01期

关键词：

rheumatoid arthritis; treatment; tumor necrosis factor-alpha; monoclonal antibody; infliximab; etanercept; cytokine blockade; disease-modifying drug;

D O I：

10.1159/000048164

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Chimeric, humanized and fully human monoclonal antibodies directed against tumor necrosis factor-alpha as well as TNF receptor constructs can be administered relatively safely during long-term use for the treatment of rheumatoid arthritis (RA). Their therapeutic efficacy in patients refractory to treatment with conventional disease-modifying drugs was proven in large clinical trials and their ability to slow the progression of disease was demonstrated radiographically. The insights into the pathophysiology of RA provided by the beneficial effects of blocking proinflammatory cytokines will lead to further drug development for this destructive autoimmune disease. Copyright (C) 2002 S. Karger AG, Basel.

引用

页码：10 / 14

页数：5

共 66 条

[41] Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].

Moreland, LW ;

Baumgartner, SW ;

Schiff, MH ;

Tindall, EA ;

Fleischmann, RM ;

Weaver, AL ;

Ettlinger, RE ;

Cohen, S ;

Koopman, WJ ;

Mohler, K ;

Widmer, MB ;

Blosch, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147

[42]

Moreland LW, 2001, J RHEUMATOL, V28, P1238

[43] Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells [J].

Nakada, MT ;

Tam, SH ;

Woulfe, DS ;

Casper, KA ;

Swerlick, RA ;

Ghrayeb, J .

CELL ADHESION AND COMMUNICATION, 1998, 5 (06) :491-503

[44] Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis [J].

Paleolog, EM ;

Hunt, M ;

Elliott, MJ ;

Feldmann, M ;

Maini, RN ;

Woody, JN .

ARTHRITIS AND RHEUMATISM, 1996, 39 (07) :1082-1091

[45] Pathogenesis of rheumatoid arthritis - The role of T cells and other beasts [J].

Panayi, GS ;

Corrigall, VM ;

Pitzalis, C .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (02) :317-334

[46]

PIGUET PF, 1992, IMMUNOLOGY, V77, P510

[47]

PINCUS T, 1993, RHEUM DIS CLIN N AM, V19, P123

[48] DRUG-INDUCED LUPUS [J].

PRICE, EJ ;

VENABLES, PJW .

DRUG SAFETY, 1995, 12 (04) :283-290

[49] Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study [J].

Reinhart, K ;

Menges, T ;

Gardlund, B ;

Zwaveling, JH ;

Smithes, M ;

Vincent, JL ;

Tellado, JM ;

Salgado-Remigio, A ;

Zimlichman, R ;

Withington, S ;

Tschaikowsky, K ;

Brase, R ;

Damas, P ;

Kupper, H ;

Kempeni, J ;

Eiselstein, J ;

Kaul, M .

CRITICAL CARE MEDICINE, 2001, 29 (04) :765-769

[50] Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease [J].

Rutgeerts, P ;

D'Haens, G ;

Targan, S ;

Vasiliauskas, E ;

Hanauer, SB ;

Present, DH ;

Mayer, L ;

Van Hogezand, RA ;

Braakman, T ;

DeWoody, KL ;

Schaible, TF ;

Van Deventer, SJH .

GASTROENTEROLOGY, 1999, 117 (04) :761-769

← 1 2 3 4 5 6 7 →